株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Jeil Pharmaceutical Co., Ltd.- 製品パイプラインレビュー

Jeil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 294004
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.82円で換算しております。
Back to Top
Jeil Pharmaceutical Co., Ltd.- 製品パイプラインレビュー Jeil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016
出版日: 2016年08月17日 ページ情報: 英文 46 Pages
概要

Jeil Pharmaceutical Co., Ltd.は韓国に本社を置く創薬企業で、APIおよび最終剤形の研究開発、製造、商品化を行っています。錠剤、注射、パッチといった最終製品の生産や、抗生物質のAPIを製造しています。

当レポートでは、Jeil Pharmaceutical Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Jeil Pharmaceutical Co., Ltd.の基本情報

  • Jeil Pharmaceutical Co., Ltd.の概要
  • 主要情報
  • 企業情報

Jeil Pharmaceutical Co., Ltd.:R&Dの概要

  • 主な治療範囲

Jeil Pharmaceutical Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Jeil Pharmaceutical Co., Ltd.:パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

Jeil Pharmaceutical Co., Ltd.:薬剤プロファイル

  • JLP-1207
  • JLP-1310
  • JLP-1401
  • JPI-289
  • JGK-263
  • Small Molecule for Degenerative Arthritis
  • Small Molecule for Hypertriglyceridaemia
  • Stem Cell Therapy for Parkinson's Disease and Age-Related Macular Degeneration
  • JJP-1305
  • JLP-1302
  • JLP-1311
  • JPI-283

Jeil Pharmaceutical Co., Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Jeil Pharmaceutical Co., Ltd.:最近のパイプライン情報

Jeil Pharmaceutical Co., Ltd.:開発休止中のプロジェクト

Jeil Pharmaceutical Co., Ltd.:企業理念

Jeil Pharmaceutical Co., Ltd.:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

目次
Product Code: GMDHC08119CDB

Summary:

Global Markets Direct's, 'Jeil Pharmaceutical Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Jeil Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Jeil Pharmaceutical Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Jeil Pharmaceutical Co., Ltd.
  • The report provides overview of Jeil Pharmaceutical Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Jeil Pharmaceutical Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Jeil Pharmaceutical Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Jeil Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Jeil Pharmaceutical Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Jeil Pharmaceutical Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Jeil Pharmaceutical Co., Ltd. Snapshot
    • Jeil Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Jeil Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Jeil Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Jeil Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Jeil Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Jeil Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Jeil Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Jeil Pharmaceutical Co., Ltd. - Drug Profiles
    • (solifenacin succinate + tamsulosin hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JLP-1401
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • metformin hydrochloride + rosuvastatin calcium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JJP-1305
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JPI-289
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JGK-263
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JLP-1601
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JLP-1604
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JP-1366
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JP-2266
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JPI-547
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Degenerative Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Hypertriglyceridaemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Parkinson's Disease and Age-Related Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JLP-1602
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • JLP-1603
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit FLT3 for Acute Myeloid Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Jeil Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Jeil Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Jeil Pharmaceutical Co., Ltd. - Dormant Projects
  • Jeil Pharmaceutical Co., Ltd. - Company Statement
  • Jeil Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Jeil Pharmaceutical Co., Ltd., Key Information
  • Jeil Pharmaceutical Co., Ltd., Key Facts
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Indication, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Jeil Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Jeil Pharmaceutical Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Jeil Pharmaceutical Co., Ltd. - Phase III, 2016
  • Jeil Pharmaceutical Co., Ltd. - Phase I, 2016
  • Jeil Pharmaceutical Co., Ltd. - Preclinical, 2016
  • Jeil Pharmaceutical Co., Ltd. - Discovery, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Jeil Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2016
  • Jeil Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2016
  • Jeil Pharmaceutical Co., Ltd., Other Locations

List of Figures

  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2016
  • Jeil Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Target, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2016
  • Jeil Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top